SCHEMBL5864896

SCHEMBL5864896

COc1ccc2[nH]c(C(=O)N3CC(CCl)c4c3cc(OCc3ccccc3)c3ncccc43)cc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 4/20 0.44
SRD5A2 P31213 2/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
IDO1 P14902 1/20 0.41
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40
NPC1 O15118 2/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
SRD5A1 P18405 1/20 0.40
FPR2 P25090 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865132 0.91 PDGFRB (0.45) FLT3MEN1KMT2AKDM4ESRD5A2
SCHEMBL5864982 0.88 DRD2 (0.44) FLT3MEN1KMT2AKDM4EPDGFRB
SCHEMBL5865127 0.86 P4HB (0.47) MEN1KMT2AKDM4ESRD5A2ALDH1A1
SCHEMBL19886126 0.84 FLT3 (0.46) FLT3MEN1KMT2AKDM4ESRD5A2
SCHEMBL6514433 0.83 KDM4E (0.52) FLT3MEN1KMT2AKDM4ESRD5A2
SCHEMBL6514438 0.83 KDM4E (0.52) FLT3MEN1KMT2AKDM4ESRD5A2
SCHEMBL31697958 0.82 GRIN2D (0.46) FLT3MEN1KMT2AKDM4ESRD5A2
SCHEMBL6517364 0.81 ADH1A (0.53) FLT3MEN1KMT2AKDM4ECYP1A2
SCHEMBL6517359 0.81 ADH1A (0.53) FLT3MEN1KMT2AKDM4ECYP1A2
SCHEMBL2399027 0.81 MEN1 (0.49) FLT3MEN1KMT2AKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064117-B2 Anti-cancer 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium AUCKLAND UNISERVICES LIMITED (NZ) 2006-06-20 US disclosed
US-20050038249-A1 Anti-cancer 2,3-dihydro-1H-pyrrole[3,2-f] quinoline compolexes of cobalt and chromium AUCKLAND UNISERVICES LIMITED (NZ) 2005-02-17 US disclosed
US-20040138195-A1 Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f[quinoline complexes of cobalt and chromium AUCKLAND UNISERVICES LIMITED (NZ) 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138195-A1 Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f[quinoline complexes of cobalt and chromium IDH1, HIF1AN, CA2 FLT3 1097/4885MEN1 1656/4885KMT2A 842/4885
US-20050038249-A1 Anti-cancer 2,3-dihydro-1H-pyrrole[3,2-f] quinoline compolexes of cobalt and chromium CA2, HIF1AN, PPOX FLT3 1163/4885MEN1 1459/4885KMT2A 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.